Document:

Exhibit

FOURTH AMENDMENT TO LEASE DATED JUNE 29, 2018

Nancy Ridge Technology Center, L.P., a California limited partnership (“Lessor”), and Cidara Therapeutics, Inc., a Delaware corporation, (“Lessee”), hereby amend the Lease dated June 9, 2014 (as previously amended, the “Lease”), for Suites #101 through #105 at 6310 Nancy Ridge Drive, San Diego, CA 92121 (“Premises”) as follows:

		
	1)
	Expiration Date:  The Lease Term is hereby extended and the Expiration Date shall be December 31, 2021.  Lessee continues to have the right to exercise the options to extend the term of the Lease pursuant to the terms and conditions of Paragraph 57 of the addendum to the Lease.

		
	2)
	Increase in Base Rent:  On January 1, 2019 the Base Rent shall increase to $69,649.30 per month.  On January 1, 2020, and every twelve (12) months thereafter, the Base Rent shall increase three percent (3%).

		
	3)
	HVAC:  Provided (a) Lessee has not modified the HVAC system, (b) Lessee has properly maintained the HVAC system, and (c) Lessor has reasonably approved the repair in advance of such repair being done, then, for each repair or replacement of a HVAC unit that is over twelve (12) years old, Lessee shall be responsible for the first $500 of the required repair or replacement, and Lessor shall be responsible any amount over $500 until after the HVAC unit is replaced with a new HVAC unit, at which time Lessee shall be responsible for all repair and replacement costs for the new HVAC unit.  Notwithstanding the foregoing, Lessor shall continue to have the obligation to replace, when needed and without any reimbursement from Lessee, the HVAC units described in Paragraph 4 of the Third Amendment to Lease.  A schedule of the HVAC units is attached as Exhibit A hereto.  Except as provided in this paragraph, Lessor's and Lessee's obligations with respect to maintenance, repair, and replacement of HVAC units that service the Premises remain unchanged, including, (1) all maintenance costs for all HVAC units shall remain Lessee’s sole responsibility and (2) Lessor's and Lessee's obligations described in Paragraph 4 of the Third Amendment to Lease are not amended by this paragraph.

		
	4)
	Tenant Improvements:  Lessor waives any restoration rights as to tenant improvements approved by Lessor prior to the date of this Amendment, and specifically Lessee shall not be required to restore the offices removed at the rear of Suite #103 to create rooms #307, #309, #310 and #316.

		
	5)
	Option to Expand: Provided Lessee has not Defaulted (whether subsequently cured or not) under any of the terms of the Lease, then, subject to any existing rights of any other tenants of the Project, Lessee shall have the option to lease any vacant space controlled by Lessor in 6310 or 6330 Nancy Ridge Drive in its as-is condition without warranty at the same terms and conditions in the Lease (as amended by this Amendment), including the same rate of Base Rent/sf, Base Rent increases, and Expiration Date; however, Lessee's Share shall be increased based upon the added area of the Expansion Space (defined below).  To exercise the option, Lessee must, on or before September 30, 2019, deliver to Lessor written notice that states (1) Lessee is exercising the option, (2) the vacant space that Lessee desires to lease, which space must be (i) one or more full suites and (ii) fully demised from other spaces in the building (such space described in the notice is herein referred to as "the Expansion Space"), and (3) the date Lessee wants to take possession of the Expansion Space, which date shall not be later than 15 days after 

the date of Lessee's notice.  All provisions of the Lease, including Lessee's obligation to pay Rent, shall apply to the Expansion Space commencing on the earlier of (1) the date Lessee takes possession of the Expansion Space or (2) the date specified in Lessee's notice.  Lessee's option under this paragraph shall not apply to any vacant space with respect to which Lessor has received an acceptable letter of intent to lease prior to the date Lessee delivers Lessee's notice exercising Lessee's option.

		
	6)
	Special Option re 6330 Nancy Ridge Drive, Suite 104.  This paragraph is agreed to by Lessor and Lessee with reference to the following facts:  (1) the premises commonly known as 6330 Nancy Ridge Drive, Suite 104 (the "IVS Space") is currently occupied by IVS Technologies, Inc., pursuant to a lease (the "IVS Lease") between Lessor and IVS Technologies, Inc., (2) IVS is actively attempting to sublease the IVS Space, and (3) Lessee may desire to sublease the IVS Space for the remaining term of the IVS Lease, provided that Lessor agrees to a direct lease with Lessee for the IVS Space for the period commencing on the expiration date of the IVS Lease and ending on the Expiration Date of the Lease.  Based upon such facts, Lessor and Lessee agree, if prior to July 31, 2018 ("the Special Option Expiration Date"), Lessee and IVS Technologies, Inc. enter into a sublease for the IVS Space, then (1) Lessor shall not unreasonably withhold Lessor's consent to such sublease and (2) Lessee shall have the option to lease the IVS Space in its as-is condition without warranty at the same terms and conditions in the Lease (as amended by this Amendment), including the same rate of Base Rent/sf, Base Rent increases, and Expiration Date; however, (1) the terms of the Lease, including the obligation to pay Rent, shall apply to the IVS Space commencing upon expiration or earlier termination the IVS Lease and (2) Lessee's Share shall be increased based upon the added area of the IVS Space.  To exercise the option, Lessee must, on or before July 31, 2018, (1) enter into a sublease with IVS Technologies, Inc. pertaining to the IVS Space, (2) have received Lessor's consent to such sublease, and (3) deliver to Lessor written notice that states Lessee is exercising the option.  Lessor agrees that, if prior to the Special Option Expiration Date Lessor receives from IVS Technologies, Inc., a written request for Lessor to consent to a sublease of the IVS Space with anyone other than Lessee, Lessor shall promptly after receiving such request advise Lessee that Lessor has received such request; however, Lessor shall not be obligated to provide to Lessee any information concerning the terms and conditions of such proposed sublease.

		
	7)
	Confidentiality: The terms of the Lease are confidential.  No party to the Lease shall disclose any of the terms of the Lease to any other party, provided that Lessee may disclose such terms to Lessee's employees, directors, officers, agents and proposed transferees.

		
	8)
	No Default: To each party's knowledge, neither party is currently in Default or Breach of any of the terms or conditions of the Lease.

		
	9)
	Authority to Execute: Each person executing this Amendment represents and warrants to all parties that he or she is duly authorized to execute and deliver this Amendment on behalf of that party.

All other terms and conditions of the Lease shall remain in full force and effect.  All capitalized terms used herein but not defined herein shall have the meanings ascribed thereto in the Lease.

		
	Lessor:
	Nancy Ridge Technology Center, L.P., a California Limited Partnership

		
	By:
	Nancy Ridge Technology Center, LLC, a California Limited Liability Company, 

its General Partner

By:                                
Chris Loughridge, its Manager    

Lessee:        Cidara Therapeutics, Inc., a Delaware corporation 

By:                                

Printed:    Matthew Onaitis

Title:    CFO & General Counsel

Schedule of Exhibits

Exhibit A--Schedule of HVAC Units

Exhibit A--HVAC SCHEDULE
	
							
	HVAC UNITS  (3/28/18)

	 
	 
	 
	 
	 
	 
	 

	HVAC COVERED BY LEASE

	Unit number
	# on unit
	model number
	serial number
	manufacturer
	year of man.
	age

	 
	 
	 
	 
	 
	 
	 

	101-1
	101-1
	50EZ-A24-30
	2614C13907
	Carrier
	2014
	4 years

	101-2
	101-2
	RQPL-B042CK  000
	F231700029
	Rheem
	2017
	1 year

	101-3
	101-3
	50TCQD12A2A5A0A0A0A0
	3812G50170
	Carrier
	2012
	6 years

	101-4
	101-4
	50EZ-A48-50
	2814C41445
	Carrier
	2014
	4 years

	101-5
	101-5
	unknown
	unknown
	Carrier
	1987
	31 years

	101-6
	101-6
	50TCQDU8A2A5A0A0A0
	2616P97919
	Carrier
	2016
	2 years

	101-7
	101-7
	50TJQ009-501
	4498G30498
	Carrier
	1998
	20 years

	102-1
	102-1
	50TCQD09A2A5A0A0A0
	0716P60797
	Carrier
	2016
	2 years

	102-2
	102-2
	YHJD60S43S5A
	W1K4091677
	York
	2014
	4 years

	102-3
	102-3
	B1HA024A06B
	(s) NHHM110673
	York
	1999
	19 years

	102-4
	102-4
	B3CH060A25ECC
	(s) NMHM159010
	York
	1999
	19 years

	102-5
	102-5
	B3CH120A25ECB
	(s) NLHM144215
	York
	1999
	19 years

	102-6
	102-6
	B3CH090A25ECB
	(s) NMHM161575
	York
	1999
	19 years

	103 new
	103-3
	50VT-B24-30TP
	2715C12842
	Carrier
	2015
	3 years

	103-4
	103-4
	50EZ-A24-30
	4311C15143
	Carrier
	2011
	7 years

	103-5
	103-5
	50TCQA04A2A5A0A0A0
	4111C59853
	Carrier
	2011
	7 years

	103-6
	103-6
	50TCQA05A2A5A0A0A0
	3511C57334
	Carrier
	2011
	7 years

	103-7
	103-7
	WCC024F100BB
	L393RY42H
	Trane
	1996
	22 years

	103-8
	103-8
	out of service
	 
	 
	 
	 

	old
	103-9
	WCG036F100BB
	391PLWH
	Trane
	1999
	19 years

	old
	103-10
	WCC024F100BB
	3925BM2H
	Trane
	1996
	22 years

	104-1
	104-1
	CPH060XXX3BXXXBA
	1007418928
	Goodman
	2010
	8 years

	104-2
	104-2
	CPH060XXX3BXXXBA
	1007418931
	Goodman
	2010
	8 years

	104-3
	104-3
	RQKA-A030JK 000
	5616F519712489
	Rheem
	1997
	21 years

	105-11
	105-11
	50TCQA04A2A5A0A0A0
	0415C55917
	Carrier
	2015
	3 years

	105-12
	105-12
	38AYC048320
	1700E00271
	Carrier
	2000
	8 years

	105-13
	105-13
	RQKA-A030JK 000
	6516F429706089
	Rheem
	1997
	21 years

	105-14
	105-14
	48GS-060090501
	0700G10083
	Carrier
	2000
	8 years

	105-5
	105-15
	48TCDD12AZA5A0A0A0
	1115P62329
	Carrier
	2015
	3 years

	105-6
	105-16
	48TCDD12A2A5A0A0A0
	1615P42764
	Carrier
	2015
	3 years

	 
	 
	 
	 
	 
	 
	 

	HVAC 6330 NRD

	suite 104 1st. Fl
	AC-3
	 
	3311C56083
	Carrier
	2011
	7 years

	suite 104 1st. Fl
	AC-4
	 
	1012C66081
	Carrier
	2012
	6 years

	suite 104 1st. Fl
	AC-5
	 
	1212C85580
	Carrier
	2012
	6 yearsExhibit 10.1

 

SUBSCRIPTION AGREEMENT

 

This Subscription
Agreement (this “Agreement”) is made as of the date set forth on the signature page hereto,
by and among Bionik Laboratories Corp.,
a Delaware corporation (the “Company”), and the subscribers identified on the signature pages hereto
(each, a “Subscriber” and collectively, the “Subscribers”).

 

Recitals

 

Whereas,
the Company seeks to sell up to US$6,000,000 in Convertible Promissory Notes in the form annexed hereto as Exhibit
A (each, a “Note” and collectively, the “Notes”) pursuant to Section
4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), Rule 506(b) of Regulation D
and/or Regulation S as promulgated under the Securities Act (the “Offering”); and

 

Whereas,
the Subscribers wish to purchase Notes in the amount set forth on (the “Subscription Amount”) their respective
Signature Page to this Agreement.

 

Now,
Therefore, in consideration of
the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, the Company and the Subscribers hereby agree as follows:

 

1.       PURCHASE
OF CONVERTIBLE PROMISSORY NOTES.

 

1.1       Subscription.
Subject to the terms and conditions herein, the Subscribers will loan to the Company such amounts, and the Company shall borrow
from the Subscribers, in accordance with the Subscription Amounts and at such dates as mutually agreed upon between the Company
and the Subscribers (each such date, a “Funding Date”).

 

1.2       Payment
for Subscription. Each Subscriber agrees that the Subscription Amount to the Company for the amount of the Subscriber’s
Subscription is to be made upon the Initial Closing (as defined below) and on each additional Closing (as defined below), by check
or by wire transfer to an account designated by the Company.

 

1.3       Closing.

 

(a)       The
closing of the subscriptions for the Notes shall occur on each Funding Date (collectively, the “Closings”
and each, without distinction, a “Closing”). Each Closing shall be held remotely by the electronic exchange
of documents and funds at such time and by such means upon which the Company and the Subscribers purchasing the Notes at such Closing
shall agree.

 

(b)       At
each Closing, the Company shall deliver to the Subscribers executed Notes in the amounts determined for each Purchaser pursuant
to this Section 1.

 

2.       REPRESENTATIONS
AND WARRANTIES.

 

2.1       Representations
and Warranties by the Company. The Company represents and warrants to each Subscriber that:

 

     1

     

    

 

(a)       Authorization.
The Company has all corporate right, power and authority to enter into this Agreement and to consummate the transactions contemplated
hereby. All corporate action on the part of the Company, its directors and stockholders necessary for the: (i) authorization execution,
delivery and performance of this Agreement by the Company; (ii) authorization, sale, issuance and delivery of the Notes contemplated
hereby and the performance of the Company’s obligations hereunder; and (iii) authorization, issuance and delivery of the
securities issuable upon conversion of the Notes (other than the Company having to increase its authorized shares of common stock
as contemplated in Section 3.2(a) of the Notes), has been taken. The securities issuable upon conversion of the Notes will be validly
issued, fully paid and nonassessable.

 

(b)       Enforceability.
Assuming this Agreement has been duly and validly authorized, executed and delivered by the parties hereto and thereto other than
the Company, this Agreement is duly authorized, executed and delivered by the Company constitutes the legal, valid and binding
obligations of the Company enforceable against the Company in accordance with its terms, except as such enforcement is limited
by general equitable principles, or by bankruptcy, insolvency and other similar laws affecting the enforcement of creditors rights
generally.

 

(c)       No
Violations. The execution, delivery and performance of this Agreement and the Notes by the Company and the consummation by
the Company of the transactions contemplated hereby and thereby will not (i) result in a violation of the Certificate of Incorporation
of the Company or other organizational documents of the Company, (ii) conflict with, or constitute a default (or an event which
with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration
or cancellation of, any agreement, indenture or instrument to which the Company is a party, or (iii) result in a violation of any
law, rule, regulation, order, judgment or decree applicable to the Company by which any property or asset of the Company is bound
or affected.

 

2.2       Disclaimer.
It is specifically understood and agreed by each Subscriber that the Company has not made, nor by this Agreement shall be construed
to make, directly or indirectly, explicitly or by implication, any representation, warranty, projection, assumption, promise, covenant,
opinion, recommendation or other statement of any kind or nature with respect to the anticipated profits or losses of the Company,
except as otherwise provided with this Agreement.

 

2.3       Representations
and Warranties by the Subscribers. Each Subscriber represents and warrants to the Company that:

 

(a)       The
Subscriber is acquiring the Notes for the Subscriber’s own account, as principal, for investment purposes only and not with
any intention to resell, distributes or otherwise dispose of the Notes, in whole or in part.

 

(b)       The
Subscriber has had an unrestricted opportunity to: (i) obtain information concerning the Offering, including the Notes, the Company
and its proposed and existing business and assets; and (ii) ask questions of, and receive answers from the Company concerning the
terms and conditions of the Offering and to obtain such additional information as may have been necessary to verify the accuracy
of the information contained in the this Agreement or otherwise provided.

 

     2

     

    

 

(c)       The
Subscriber has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and
risks of investing in the Company, and all information that the Subscriber has provided concerning the Subscriber, the Subscriber’s
financial position and knowledge of financial and business matters is true, correct and complete.

 

(d)       The
Subscriber has relied solely on the advice of, or has consulted with, in regard to the legal, investment and tax considerations
involved in the purchase, ownership and disposition of Notes, the Subscriber’s own legal counsel, business and/or investment
adviser, accountant and tax adviser.

 

(e)       If
the Subscriber is an entity, the Subscriber is duly organized, validly existing and in good standing under the laws of its jurisdiction
of incorporation or organization, as the case may be. The Subscriber has all requisite power and authority to own its properties,
to carry on its business as presently conducted, to enter into and perform this Agreement, the Notes and the agreements, documents
and instruments executed, delivered and/or contemplated hereby (collectively, the “Subscription Documents”)
to which it is a party and to carry out the transactions contemplated hereby and thereby. The Subscription Documents are valid
and binding obligations of the Subscriber, enforceable against it in accordance with their terms, except as enforceability may
be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar laws, from time to time in effect, which
affect enforcement of creditors’ rights generally. If applicable, the execution, delivery and performance of the Subscription
Documents to which it is a party have been duly authorized by all necessary action of the Subscriber. The execution, delivery and
performance of the Subscription Documents and the performance of any transactions contemplated by the Subscription Documents will
not: (i) violate, conflict with or result in a default (whether after the giving of notice, lapse of time or both) under any contract
or obligation to which the Subscriber is a party or by which it or its assets are bound, or any provision of its organizational
documents (if an entity), or cause the creation of any lien or encumbrance upon any of the assets of the Subscriber; (ii) violate,
conflict with or result in a default (whether after the giving of notice, lapse of time or both) under, any provision of any law,
regulation or rule, or any order of, or any restriction imposed by any court or other governmental agency applicable to the Subscriber;
(iii) require from the Subscriber any notice to, declaration or filing with, or consent or approval of any governmental authority
or other third party other than pursuant to federal or state securities or blue sky laws; or (iv) accelerate any obligation under,
or give rise to a right of termination of, any agreement, permit, license or authorization to which the Subscriber is a party or
by which it is bound.

 

(f)       At
the time the Subscriber was offered the Notes, it was, and at the date hereof it is, and on each Funding Date and date on which
the Subscriber converts the Notes the Subscriber will be, an “accredited investor” as defined in Rule 501(a) under
the Securities Act. The Subscriber hereby represents that neither the Subscriber nor any of its Rule 506(d) Related Parties is
a “bad actor” within the meaning of Rule 506(d) promulgated under the Securities Act. For purposes of this Agreement,
“Rule 506(d) Related Party” shall mean a person or entity covered by the “Bad Actor disqualification”
provision of Rule 506(d) of the Securities Act.

 

     3

     

    

 

3.       MISCELLANEOUS.

 

3.1       Addresses
and Notices. All notices, demands, consents, requests, instructions and other communications to be given or delivered
or permitted under or by reason of the provisions of this Agreement or in connection with the transactions contemplated hereby
shall be in writing and shall be deemed to be delivered and received by the intended recipient as follows: (i) if personally delivered,
on the business day of such delivery (as evidenced by the receipt of the personal delivery service); (ii) if mailed certified or
registered mail return receipt requested, two (2) business days after being mailed; or (iii) if delivered by overnight courier
(with all charges having been prepaid), on the business day of such delivery (as evidenced by the receipt of the overnight courier
service of recognized standing). If any notice, demand, consent, request, instruction or other communication cannot be delivered
because of a changed address of which no notice was given (in accordance with this Section 3.1, or the refusal to accept
same, the notice, demand, consent, request, instruction or other communication shall be deemed received on the second business
day the notice is sent (as evidenced by a sworn affidavit of the sender). All such notices, demands, consents, requests, instructions
and other communications will be sent to the following addresses or facsimile numbers as applicable:

 

	If to the Company to:	 	
        Bionik Laboratories Corp.

        483 Bay Street, N105

        Toronto, ON M5G 2C9

        Attention: CEO

	 	 	 
	With copies to:	 	
        Ruskin Moscou Faltischek, PC

        1425 RXR Plaza

        East Tower, 15th Floor

        Uniondale, New York 11556

        Attention: Stephen E. Fox, Esq.

	 	 	 

If to the Subscriber, to the address set
forth on the signature page annexed hereto.

 

Any such person may by notice given in
accordance with this Section 3.1 to the other parties hereto designate another address or person for receipt by such person
of notices hereunder.

 

3.2       Titles
and Captions. All Article and Section titles or captions in this Agreement are for convenience only. They shall not
be deemed part of this Agreement and do not in any way define, limit, extend or describe the scope or intent of any provisions
hereof.

 

3.3       Assignability.
This Agreement is not transferable or assignable by the undersigned.

 

3.4       Pronouns
and Plurals. Whenever the context may require, any pronoun used herein shall include the corresponding masculine, feminine
or neuter forms. The singular form of nouns, pronouns and verbs shall include the plural and vice versa.

 

     4

     

    

 

3.5       Further
Action. The parties shall execute and deliver all documents, provide all information and take or forbear from taking
all such action as may be necessary or appropriate to achieve the purposes of this Agreement. Each party shall bear its own expenses
in connection therewith.

 

3.6       Applicable
Law. This Agreement shall be construed in accordance with and governed by the laws of the State of Delaware without
regard to its conflict of law rules.

 

3.7       Binding
Effect. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs,
administrators, successors, legal representatives, personal representatives, permitted transferees and permitted assigns. If the
undersigned is more than one person, the obligation of the undersigned shall be joint and several and the agreements, representations,
warranties and acknowledgments herein contained shall be deemed to be made by and be binding upon each such person and such person’s
heirs, executors, administrators and successors.

 

3.8       Integration.
This Agreement, together with the remainder of the Subscription Documents of which this Agreement forms a part, constitutes the
entire agreement among the parties pertaining to the subject matter hereof and supersedes and replaces all prior and contemporaneous
agreements and understandings, whether written or oral, pertaining thereto. No covenant, representation or condition not expressed
in this Agreement shall affect or be deemed to interpret, change or restrict the express provisions hereof.

 

3.9       Amendment.
 This Agreement and the Notes may be amended only with the written consent of the Company and the holders of a majority
of the aggregate principal amount of the Notes (a “Majority in Interest”). The conditions or observance
of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively)
only by written instrument and with respect to conditions or performance obligations benefiting the Company, by the Company, and
with respect to conditions or performance obligations benefiting the Subscribers, only with the consent of a Majority in Interest.
Any amendment or waiver effected in accordance with this Section 3.9 shall be binding on all holders of the Notes, even
if they do not execute such amendment, consent or waiver, as the case may be.

 

3.10       Creditors.
 None of the provisions of this Agreement shall be for the benefit of or enforceable by creditors of any party.

 

3.11       Waiver.
 No failure by any party to insist upon the strict performance of any covenant, agreement, term or condition of this
Agreement or to exercise any right or remedy available upon a breach thereof shall constitute a waiver of any such breach or of
such or any other covenant, agreement, term or condition.

 

3.12       Rights
and Remedies. The rights and remedies of each of the parties hereunder shall be mutually exclusive, and the implementation
of one or more of the provisions of this Agreement shall not preclude the implementation of any other provision.

 

     5

     

    

 

3.13       Counterparts.
This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy of this Agreement
and all of which, when taken together, will be deemed to constitute one and the same agreement. In the event that any signature
is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create
a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect
as if such facsimile or “.pdf” signature page were an original thereof.

 

signatures
on the following pages

 

     6

     

    

 

In
Witness Whereof, the undersigned has executed this Agreement on this ____ day of _______________, 2018.

 

	 	 	 	 	 
	Signature of Subscriber:	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	By:	                      	 	 	 
	Name:	 	 	Print Name of Subscriber	
	Title:	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	Social Security Number(s) or EIN	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	Mailing Address of Subscriber(s)	 	Residence of Subscriber(s)	 
	 	 	 	 	 
	 	 	 	 	 
	Street	 	 	Street	 
	 	 	 	 	 
	 	 	 	 	 
	City        State       Zip Code	 	City       State       Zip Code	 
	 	 	 	 	 
	If Joint Ownership, check one:	 	 	 
	 	 	 	 	 
	 ̈ Joint Tenants with Right of Survivorship	 	 	 
	 ̈ Tenants-in-Common	 	 	 
	 ̈ Tenants by the Entirety	 	 	 
	 ̈ Community Property	 	 	 
	 ̈ Other (specify):	 	 	 
	 	 	 	 	 
	 	 	 	$	 
	 	 	 	Aggregate Subscription Amount 	 
	 	 	 	 	 
	 	 	 	Method of Payment:   ̈ Wire Transfer    ̈ Check	 

 

FOREGOING SUBSCRIPTION ACCEPTED:

 

	Bionik Laboratories Corp.	 
	 	 	 
	 	 	 
	By:	                	 
	Name:  Eric Dusseux	 
	Title: CEO 	 

 

    	 	Signature Page to Subscription Agreement
	 

     

    

 

Exhibit
A 

 

CONVERTIBLE PROMISSORY NOTE

 

[See attached]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]